Acyloxybutadiene tricarbonyl iron complexes as enzyme-triggered CO-releasing molecules (ET-CORMs): a structure-activity relationship study by Romanski, Steffen et al.
Dalton
Transactions
Dynamic Article Links
Cite this: Dalton Trans., 2012, 41, 13862
www.rsc.org/dalton PAPER
Acyloxybutadiene tricarbonyl iron complexes as enzyme-triggered
CO-releasing molecules (ET-CORMs): a structure–activity relationship study†
Steffen Romanski,a Birgit Kraus,b Miguel Guttentag,c Waldemar Schlundt,a Hannelore Rücker,d
Andreas Adler,a Jörg-Martin Neudörﬂ,a Roger Alberto,c Sabine Amslinger*d and Hans-Günther Schmalz*a
Received 22nd March 2012, Accepted 14th May 2012
DOI: 10.1039/c2dt30662j
A series of η4-acyloxycyclohexadiene–Fe(CO)3 complexes was prepared and fully characterized by
spectroscopic methods including single crystal X-ray diffraction. For this purpose a new synthetic
access to differently acylated 1,3- and 1,5-dienol–Fe(CO)3 complexes was developed. The enzymatically
triggered CO release from these compounds was monitored (detection of CO through GC and/or by
means of a myoglobin assay) and the anti-inﬂammatory effect of the compounds was assessed by a
cellular assay based on the inhibition of NO-production by inducible NO synthase (iNOS). It was
demonstrated that the properties (rate of esterase-triggered CO release, iNOS inhibition, cytotoxicity)
of the complexes strongly depend on the substitution pattern of the π-ligand and the nature of the
acyloxy substituent.
Introduction
Carbon monoxide (CO) has recently been recognized as an
important signalling molecule in mammals.1 Most of the
endogenously produced CO is generated in the course of oxi-
dative heme degradation by the heme oxygenase (HO) enzymes.
One of the isoforms of these enzymes (HO-1) is inducible and
up-regulated as a response to stress.2 CO induces several
beneﬁcial biological effects, such as cytoprotection, vasodilation,
or inhibition of inﬂammation,3 and there are clinical studies on
different medical applications.4 One attractive option to deliver
CO (avoiding the use of toxic CO gas) is the use of CO-releasing
molecules (CORMs).5 Motterlini and co-workers established
this constantly growing ﬁeld by the identiﬁcation and
evaluation of certain transition metal carbonyl complexes, such
as [Mn2(CO)10] (CORM-1), fulﬁlling this function.
6 Later, com-
pounds with improved properties were developed. A prominent
example is fac-[RuCl(glycinato)(CO)3] (1, CORM-3),
7 a water
soluble complex that releases CO under physiological conditions
and is undoubtedly the most studied CORM (Fig. 1).8 While a
number of different CORMs were shown to exhibit promising
activities in various biological investigations,9 an important
unsolved challenge is the delivery of controlled amounts of CO
to a target tissue. A general strategy to achieve this aim is the use
of stable molecules, which release CO only after activation by
means of a trigger.10 Two possibilities are (1) the pH-dependent
CO release from boranocarbonate (2, CORM-A1)11 or amino-
derivatives thereof,12 or (2) the UV-triggered CO release from
transition metal carbonyl complexes.13
As a novel concept, we recently introduced acyloxybutadiene–
Fe(CO)3 complexes of type 3 as enzyme-triggered CO-releasing
molecules (ET-CORMs).14 The earlier observation, that enol
complexes of type 4 are labile and decompose under oxidative
conditions, suggested their suitability as CORMs (Scheme 1).
As stable (and “storable”) precursors we devised the correspond-
ing esters, i.e. acyloxydiene complexes of type 3, which are
sufﬁciently stable under physiological conditions but are readily
converted to the “active” species 4 by means of enzymatic
hydrolysis. Thus, once a complex of type 3 enters a cell, clea-
vage of the ester function by an intracellular esterase triggers the
desired CO-release by generating the labile enol complex 4. The
oxidative decomposition of this type of intermediate (presum-
ably via a 16-VE species of type 5) leads to the liberation of the
enone ligand and to the release of three molecules of CO
(Scheme 1).
Fig. 1 Structures of CORM-3 (1) and CORM A1 (2).
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In our initial study we succeeded in proving the concept, i.e.
the enzyme-triggered CO-release from compounds of type 3, by
synthesis and evaluation of complexes rac-6, rac-7, rac-8 and
rac-9 (Scheme 2, inner circle). These compounds showed very
promising effects in a cellular assay based on the inhibition of
NO-production by inducible NO-synthase (iNOS). Moreover, a
strong dependency of the reactivity (towards enzymatic ester
hydrolysis) and the biological activity on the structure of the
complexes was observed. These interesting results prompted us
to further explore this class of compounds. We here disclose the
results of a much more detailed study, which has led to the
identiﬁcation of pronounced structure–activity relationships.
Results and discussion
Synthesis
The various acyloxydiene–Fe(CO)3 complexes used in the
present study are displayed in Fig. 2. Compounds rac-6, rac-7
and rac-8 were synthesized as described before.14 Di-acetates
rac-9 and rac-16 were prepared using a slightly modiﬁed version
of the Boháč procedure.15 Complex rac-10 was synthesized from
cyclohexenone (19) by deprotonation with LiHMDS in the pres-
ence of TPPA (2.5 equiv.) followed by O-acylation of the result-
ing dienolate with pivaloyl chloride (PivCl). The resulting
dienyl pivalate 20 was treated with Fe2(CO)9 in reﬂuxing diethyl
Scheme 1 Proposed mechanism of action of enzyme-triggered CO-
releasing molecules (ET-CORMs) of type 3.
Scheme 2 Synthesis of complex rac-10. (a) LiHMDS, TPPA, THF,
−78 °C, then PivCl; (b) Fe2(CO)9, Et2O, 40 °C, 16 h. LiHMDS: lithium
hexamethyldisilazide; PivCl: pivaloyl chloride; TPPA: trispyrrolidino
phosphoric acid triamide.
Fig. 2 Acyloxydiene–Fe(CO)3 complexes used in this study as potential ET-CORMs for the evaluation of structure–activity relationships. Com-
pounds rac-6, rac-7, rac-8 and rac-9 were reported in our previous study.14 The focus of this study is the variation of the structural elements marked in
red, i.e. the type of the ester group and additional methyl substituents at the cyclohexene ring.
This journal is © The Royal Society of Chemistry 2012 Dalton Trans., 2012, 41, 13862–13875 | 13863
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ether to generate the desired complex rac-10 in good yield
(Scheme 2).
The three complexes rac-11, rac-12 and rac-13 were synthe-
sized in a similar manner, starting from different cyclohexe-
nones. Compound rac-11 was prepared starting from
4,4-dimethylcyclohexenone (21)16 by deprotonation with LDA
and trapping of the resulting dienolate with Ac2O. Complexation
of the resulting dienyl acetate 22 then afforded rac-11 (Scheme 3).
Complexes rac-12 and rac-13 were synthesized from 5,5-
dimethylcyclohexenone (23), which was obtained from dime-
done (27) using the two-step protocol of Wawrzénczyk and
Lochyński.17 Regioselective deprotonation of 23 under either
kinetic (LDA, THF) or thermodynamic (LiHMDS, TPPA)14
control, subsequent O-acetylation and ﬁnal complexation led to
rac-12 and rac-13, respectively, as pure isomers after chromato-
graphy (Scheme 4).
The complexes rac-14 and rac-15 were readily obtained from
the 1,3-diketones 26 or 27 in a three-step procedure. At ﬁrst, the
β-pivaloxy-substituted enones (vinylogous anhydrides) 28 and
29, respectively, were prepared. Subsequent deprotonation with
LDA, O-pivaloylation of the enolate intermediates and com-
plexation then afforded the desired products (Scheme 5).18
An attempt to apply a related protocol to the synthesis of the
dienyl palmitate complexes rac-17 and rac-18 failed, because we
could not achieve the synthesis of the dienyl palmitates (as com-
plexation precursors). The problem was solved (according to the
strategy of Yeh and Hwu)19 by ﬁrst preparing a siloxy-substi-
tuted complex (rac-34/35) and subsequently replacing the silyl
by an acyl unit (Scheme 6). The siloxydiene 32 was obtained
from 19 with LDA and TMSCl. Subsequent complexation
afforded rac-34 which, without isolation, was deprotected by
chromatography on SiO2 under inert conditions (N2) to give the
dienol complex rac-36. This sensitive compound was immedi-
ately converted to the desired ester rac-17 with NaH and the acid
chloride. A drawback of this sequence is the low yield (and low
reproducibility) resulting from the necessity to isolate the highly
labile intermediate rac-36, which is a compound of type 4.
To overcome this disadvantage we deprotected the raw com-
plexation product (rac-34) by addition of TBAF and reacted
the in situ-formed dienol complex directly with NaH and the
acid chloride. This way, the desired complex rac-17 was
obtained with an improved yield and good reproducibility. Using
the TIPS-derivative 33, the siloxy-substituted diene complex
rac-34 was stable enough to be puriﬁed by chromatography and
rac-17 was obtained in a greatly improved overall yield
(Scheme 6).
The synthesis of the isomeric compound rac-18 was achieved
by applying a related methodology (Scheme 7). The TMS-pro-
tected diene, i.e. (cyclohexa-1,3-dien-1-yloxy)trimethylsilane,
was not synthesized, but the corresponding more stable TIPS
derivative 37 (obtained from 19 with LiHMDS/TPPA and
TIPSOTf) allowed us to prepare the siloxydiene complex rac-38
in excellent yield. Deprotection with TBAF and trapping of the
resulting di-enolate complex with palmitoyl chloride in the pres-
ence of a base (NaH or DIPEA) gave rise to rac-18 in high yield
(Scheme 7).
Scheme 4 (a) LDA, THF, −78 °C, then Ac2O; (b) Fe2(CO)9, Et2O,
40 °C, 16 h; (c) LiHMDS, TPPA, THF, −78 °C, then Ac2O.
Scheme 3 (a) LDA, THF, −78 °C, then Ac2O; (b) Fe2(CO)9, Et2O,
40 °C, 16 h. LDA: lithium diisopropyl amide.
Scheme 5 (a) Pyridine, DCM, 20 °C, then PivCl; (b) LDA, THF,
−78 °C, then Ac2O; (c) Fe2(CO)9, Et2O, 40 °C, 16 h.
Scheme 6 (a) LDA, THF, −78 °C, then TMSCl or TIPSOTf; (b)
Fe2(CO)9, Et2O, 40 °C, 16 h; (c) SiO2, inert conditions; (d) NaH, DMF,
0 °C, then C15H31COCl; (e) NaH, DMF, TBAF, 0 °C, then
C15H31COCl. TIPSOTf: triisopropylsilyl triﬂuoromethanesulfonate;
TBAF: tetra-n-butyl ammonium ﬂuoride.
13864 | Dalton Trans., 2012, 41, 13862–13875 This journal is © The Royal Society of Chemistry 2012
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To evaluate also the biological activity of the expected organic
by-products of the particularly active ET-CORMs (rac-9 and
rac-16), the enones 39 and 40 were required as reference sub-
stances. These compounds were prepared from the diketones 26
and 2720 by reaction with AcCl in the presence of pyridine
(Scheme 8).
X-Ray diffraction and analytics
All of the prepared acyloxydiene–Fe(CO)3 complexes (Fig. 2)
proved to be reasonably air-stable and were fully characterized
by the common spectroscopic methods. The structures of the
complexes rac-10, rac-11, rac-12, rac-14, rac-15, rac-17 and
rac-18 were additionally conﬁrmed by X-ray crystal structure
analysis (Fig. 3).
The different positions of the ester substituents, the additional
methyl substituents and the different acyl groups did not induce
any signiﬁcant change of the boat-type conformation or the bond
lengths within the cyclohexadiene ring. In all cases, the diene
moiety of the molecules is virtually planar, with C–C–C–C
torsion angles of 0.2–3.6°. The Fe(CO)3 tripod adopts a confor-
mation with one CO ligand eclipsing the Csp3–Csp3 single
bond. The molecular structures are depicted in Fig. 3. For the
X-ray crystallographic data and structural details, see Table 4 and
the ESI.†
Detection of the CO-release
Prior to the in vitro evaluation of the CO-releasing properties of
the various iron complexes, we had to identify suitable esterases
for the enzymatic hydrolysis. In the course of our previous study,
pig liver esterase (PLE) and lipase from Candida rugosa (LCR)
had proved to be most suitable (out of several commercial
esterases initially screened). For this reason we investigated the
hydrolysis of the different complexes using these enzymes. The
kinetic resolution of the (racemic) compounds was taken as
unambiguous proof of enzymatic hydrolysis. For this purpose
the enantiomeric excess of the remaining complex was deter-
mined by means of HPLC or GC on a chiral stationary phase. In
some cases (rac-14, rac-15, rac-17 and rac-18) no sufﬁcient
enantiomer separation was achieved. In these cases we used the
CO-release, as determined by the myoglobin (Mb) assay or GC
(see below), as an indirect method to prove the enzymatic clea-
vage.21 Noteworthy, PLE of high purity (130 U mg−1) was
required for the Mb assay to prevent Mb degradation by protease
impurities. Nevertheless, these impurities of the cheaper PLE
(15 U mg−1) proved to be beneﬁcial for the hydrolysis of certain
complexes (monitored by GC detection of the CO release). The
results of the various hydrolysis experiments are summarized in
Table 1.
Scheme 8 (a) Pyridine, DCM, 20 °C, then AcCl.
Scheme 7 (a) LiHMDS, TPPA, THF, −78 °C, then TIPSOTf; (b)
Fe2(CO)9, Et2O, 40 °C, 16 h; (c) TBAF, DIPEA, DMF, 20 °C, then
C15H31COCl. DIPEA: diisopropylethylamine.
Fig. 3 Molecular structures of rac-10, rac-11, rac-12, rac-14, rac-15,
rac-17 and rac-18 in the crystalline state. Ellipsoids are drawn at the
50% probability level.
Table 1 Identiﬁcation of suitable esterases (PLE or LCR) for the
cleavage of various acyloxydiene–Fe(CO)3 complexes
Substrate PLE (high purity) LCR PLE (low purity)
rac-6 −a +a +c
rac-7 −a ±a +c
rac-8 +a +a +c
rac-9 +a −a +c
rac-10 +a −a +c
rac-11 −a +a +c
rac-12 −a −a +c
rac-13 +a +a +c
rac-14 +b −b +c
rac-15 +b −b +c
rac-16 +a ±a +c
rac-17 −b ±b,c −c
rac-18 +b +c +c
Conversion was detected as follows: aBy measuring the kinetic
resolution by GC or HPLC on a chiral stationary phase. bBy detecting
the CO-release by means of the Mb-assay. cBy detecting the CO-release
through GC. PLE: pig liver esterase; LCR: lipase from Candida rugosa.
This journal is © The Royal Society of Chemistry 2012 Dalton Trans., 2012, 41, 13862–13875 | 13865
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The esterase-triggered CO-release from the compounds was
detected, but not quantiﬁed, using the myoglobin (Mb)-based
assay established by Motterlini et al.6 To obtain more precise
information on the (relative) rates and the quantities of released
CO, the enzyme-triggered CO-release of complexes rac-6 to
rac-18 was additionally monitored by GC.22 The times for the
release of 0.5 mol of CO per mol of ET-CORM (t0.5)
23 from
the different complexes under standard conditions (with the
speciﬁed enzyme) are listed in Table 2. In agreement with
the proposed chemical mechanism (Scheme 1), the enzyme-
triggered CO release from the acyloxydiene–Fe(CO)3 complexes
was found to be associated with a consumption of oxygen in the
reaction system, as indicated by a decrease of the O2 peak con-
nected to the growth of the CO peak (Fig. 4).
As a consequence, the calibration of the GC measurements to
quantify the amount of CO formed required particular effort (see
ESI†). The results shown in Table 2 reveal the following trends.
(1) The CO release from the pivalates and palmitates, respec-
tively, was slower (as compared to the acetates) which corres-
ponds to the expected slower rates of (also enzymatic)
hydrolysis.24 (2) The CO release from the complexes with an
ester function at the outer position of the diene (rac-8, rac-10
and rac-18) was much faster than the CO release from the com-
plexes with the ester function at the inner position (rac-6, rac-7
and rac-17).
This effect results either from a slower rate of ester hydrolysis
(dependent on the enzyme used), a lower stability (faster oxi-
dative decay) of the resulting enol intermediates (related to 4), or
a combined effect. (3) The CO release from the diacetate com-
plexes proved to be the fastest. This might be caused by a faster
ester hydrolysis or a lower stability of the initially formed enol
complex. It also cannot be excluded that hydrolysis of the
second ester function triggers an accelerated CO release.
Biological activity
The inducible form of NO-synthase (iNOS) is a dimeric
heme protein whose action leads to the formation of NO and
L-citrulline from L-arginine in the presence of O2 and NADPH.
25
The NO released by mammalian cells is employed against inva-
ders such as viruses, bacteria and parasites as well as tumor
growth.26 The inﬂuence of CO on the activity of the pro-inﬂam-
matory enzyme iNOS can be either on the transcriptional level
or on the protein level (Fig. 5). On the transcriptional level,
different mechanisms come into play where the activation of the
transcription factor nuclear factor-κB (NF-κB)27 can be inhibited
and thus the expression of iNOS. All three decomposition pro-
ducts of ET-CORMs, Fe3+ ions28 and CO29 as well as the corres-
ponding enones such as cyclohexenone,30 have been reported to
attenuate iNOS protein levels. Enones are of importance since
they interfere with the thiol-regulated activation of NF-κB
through Michael additions.31 On the protein level, the enzyme
activity of iNOS can be blocked with CO by either inhibiting the
formation of the active dimeric form29 of iNOS or binding of
CO to the iron center of the heme prosthetic group.32 This leads
to the deterioration of its catalytic activity to produce NO
(Fig. 5). Therefore, the ET-CORMs can act in different ways
when inhibiting the production of NO by iNOS. Both their
ability to release CO and their decomposition products (i.e. the
corresponding enones and Fe3+) or a combination thereof may
be responsible for the observed activity of the ET-CORMs. That
is also true for potential toxic effects, which may additionally be
attributed to the complexes themselves.
The biological activity of the ET-CORMs was assessed (using
the murine macrophage cell line RAW264.7) by determining
their inﬂuence on (1) the lipopolysaccharide (LPS)-induced pro-
duction of NO by iNOS and (2) the cell viability (Table 3). The
latter was determined by means of the MTT assay and crystal
violet staining, while the inhibition of NO-production was ana-
lyzed by the Griess assay.
An overview of the results (including our previous results14)
is given in Table 3. For a more detailed presentation of the data,
see Fig. 6 and the ESI.†
Table 2 Quantiﬁcation of CO-release in the monitored period and
times for the release of 0.5 mol of CO (t0.5) per mol of ET-CORM are
given
Complex Enzyme Released CO (equiv.)a Time (min)b t0.5 (min)
rac-6 LCR 2.4 10 020 n.f. 128
rac-6 PLE 2.2 5638 n.f. 43
rac-11 PLE 0.1 1877 n.f. —
rac-12 PLE 1.0 3444 n.f. 133
rac-7 PLE 0.3 4778 n.f. —
rac-17 LCR 0.6 7200 n.f. 6119
rac-8 PLE 2.4 300 n.f. 21
rac-10 PLE 2.6 2178 28
rac-13 PLE 3.1 3300 25
rac-18 PLE 1.3 1400 108
rac-16 PLE 2.1 600 10
rac-9 PLE 3.0 600 5
rac-15 PLE 2.3 4320 n.f. 51
rac-14 PLE 1.7 4320 n.f. 478
a The determination of the absolute amount of CO was complicated by
the consumption of oxygen, which varied for the individual compounds
(but always stayed in the same range). The average consumption of
oxygen was considered in the calibration, but deviations in the range of
±0.2 equiv. cannot be excluded. b In cases where the CO release still
proceeded when the detection was stopped, “n.f.” (not ﬁnished) is added
as a sufﬁx.
Fig. 4 Monitoring the CO release from rac-9 as a function of the time.
The O2 peak (left) clearly decreases while the CO peak (right) increases.
13866 | Dalton Trans., 2012, 41, 13862–13875 This journal is © The Royal Society of Chemistry 2012
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The data given in Table 3 immediately reveal compounds
rac-8, rac-9, rac-13, rac-15, and rac-16 as being most promis-
ing. Interestingly, diacetates rac-9 and rac-16, which differ
structurally only by the two additional methyl groups in the
5-position of the cyclohexadiene ring (in rac-16), show a similar
reduction of NO-formation at 5 μM (about 34%). However,
complex rac-16 is already active at 1.0 μM (7.7%) but due to its
toxicity no measurements were performed at concentrations
above 5 μM. The less toxic compound rac-9 reduced the NO-
production at concentrations ≥5.0 μM, and exhibited a remark-
able maximum effect of 66% NO-inhibition at 20 μM (the
highest non-toxic concentration). The “outer” monoacetate rac-8
also displayed good inhibition of NO production (49% at
10 μM) but proved again to be more toxic than its dimethylated
analog rac-13, which showed a particularly clear concentration
dependency of its iNOS-inhibiting effect (Fig. 6C). The dipiva-
late rac-15 was less toxic than the corresponding diacetate (rac-
16) but also signiﬁcantly less active. However, because of the
lower toxicity a higher maximum inhibition could be reached
(42% at 25 μM). Nevertheless, the most signiﬁcant inhibition of
NO-production was reached with compound rac-13 (79% at
100 μM) as a consequence of its exceptionally low toxicity.
To probe whether the observed activity is merely an effect of
CO and cannot be attributed to the enone decomposition pro-
ducts, we also tested the enones 19, 23, 39, and 40 (Fig. 7) for
their toxicity and inﬂuence on NO-production with LPS-stimu-
lated mouse macrophages.
Enone 39 is not toxic and no NO-inhibition activity was
found in the concentration range (1.0–5.0 μM) used for the
assessment of rac-16 (Fig. 6E). Therefore, the NO-inhibition
caused by rac-16 must be attributed to the CO release. A similar
outcome was obtained for rac-9 and its decomposition product,
i.e. the enone 40. However, a completely different situation was
observed for the mono-acetoxy-substituted complex rac-13
bearing two geminal methyl groups. In this case, both rac-13
and its parent enone 23 possess no toxicity but show a very
Fig. 5 Potential inﬂuences of CORMs on the transcription and protein activity of inducible NO-synthase (iNOS).25 Inducers of transcription: LPS,
lipopolysaccharide; IFN-γ, interferon-γ; ROS, reactive oxygen species/oxidative stress; IL-1β, interleukin-1β; TNF-α, tumor necrosis factor-α. Inhibi-
tors of transcription (= inhibitors of nuclear factor-κB (NF-κB) activation): glucocorticosteroids, antioxidants, transforming growth factor-β1 (TGF-β1)
or enones. IκBα, NF-κB inhibitor α.
Table 3 Biological activities of ET-CORMs: cytotoxicity data were
determined by MTT or crystal violet assay, and inhibition of NO-
production in LPS-stimulated RAW264.7 murine macrophages by Griess
assay
MTT or crystal
violet* Inhibition of NO-production (%)
Compound
IC50
(μM)
IC20
(μM)
Minimum
(conc (μM))
Maximum
(conc (μM))
At
10 μM
rac-6 67a 28a 17 (25)a 17 (25)a a,b
rac-7 >100*a >100*a —a —a —a
rac-8 40a 11a 5 (0.5)a 49 (10)a 49a
rac-9 54a 22a 33 (5)a 66 (20)a 57a
rac-10 >100 57 11 (10) 23 (50) 11
rac-11 41 11 11 (10) 11 (10) 11
rac-12 49 18 9 (5) 17 (10) 17
rac-13 >100 >100 19 (5) 79 (100) 33
rac-14 52 17 — — b
rac-15 69* 25* 16 (15) 42 (25) b
rac-16 35 5 8 (1) 34 (5) c
rac-17 >100 49 — — b
rac-18 90 31 — — b
19 62 20 12 (1) 60 (20) 55
23 >100 >100 18 (5) 83 (100) 37
39 >100 >100 12 (50) 15 (100) b
40 >100 >100 6 (10) 9 (100) 6
Signiﬁcant minimum and maximum NO-inhibition values are given at
concentrations that had no toxic effects. *An unusual color was
observed with rac-7 and rac-15 in the MTT assay prohibiting a correct
assessment of the cell viability, therefore a cell count was done via the
crystal violet assay. aValues taken from ref. 14. bNo signiﬁcant
inhibition was observed at this concentration. cNo inhibition could be
assigned due to toxicity at this concentration.
This journal is © The Royal Society of Chemistry 2012 Dalton Trans., 2012, 41, 13862–13875 | 13867
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strong NO-inhibition of 19–79% at concentrations of 5–100 μM
for rac-13 (Fig. 6C) and of 18–83% at 5–100 μM for enone 23
(see also the ESI; Fig. S28B†) which are essentially the same.
This indicates that the enone strongly contributes to the overall
activity of the complex in this case and might even exceed the
activity of the released CO.
On cleavage of the “outer” acetate complex rac-8, i.e. the
non-dimethylated derivative of rac-13, enone 19 (cyclohexe-
none) is liberated, which is a known inducer of phase 2 enzymes
through thiol-regulated Michael addition chemistry.30 Both rac-8
and 19 show equal activity in the Griess assay (10% for rac-814
and 12% NO-inhibition for 19 at 1.0 μM). However, rac-8 exhi-
bits signiﬁcant toxicity down to 10 μM whereas cyclohexenone
displays no toxicity at this concentration (see ESI, Fig. S28A†).
This observation points to a distinct CO effect causing the
toxicity of rac-8 or a toxic effect of complex rac-8 itself. Fur-
thermore, the comparison of dimethyl-substituted mono-acetoxy-
diene complexes rac-11, rac-12 and rac-13 reveals that in this
case the “inner” complexes (rac-11 and rac-12) are inferior
because of their much higher toxicity compared to rac-13. The
inner mono-pivaloate complex rac-7,14 the dimethyl-dipivaloate
rac-14, as well as both palmitates (rac-17 and rac-18) proved to
be completely unable to inhibit the production of NO, which
indicates poor or no decomposition of these complexes by the
intracellular esterases of the particular cell line.
From our biological data we can deduce the structure–activity
relationships summarized in Fig. 8. Most importantly, an “outer”
dienyl-acetate core-structure (corresponding to rac-8) proved to
be essential for high (desired) biological activity. Introduction of
more bulky ester units resulted in reduced NO-inhibition activity
together with lower toxicity. The diesters were generally more
toxic and exhibited greater NO-inhibition power as compared to
the monoesters. Geminal dimethylation at the cyclohexadiene
ring reduced the toxicity without inducing a too strong loss of
activity. Therefore, rac-9 and rac-13 are the “best” compounds,
with rac-9 being more potent but also more toxic than rac-13.
Fig. 6 Results of the in vitro assays performed with RAW264.7 cells
stimulated with 10 ng mL−1 of LPS. Charts on the left side refer to
MTT tests (crystal violet assay in the case of rac-15 (D)) after an incu-
bation time of 24 h at different concentrations. Charts on the right
display the inﬂuence of ET-CORMs on NO-production (Griess assay).
Data represent at least three independent experiments performed in quad-
ruplicate. Levels of signiﬁcance: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
Fig. 7 Structures of tested enones produced from ET-CORMs accord-
ing to the mechanism shown in Scheme 1.
Fig. 8 Inﬂuence of modiﬁcations of the parent “outer” monoacetate
rac-8 (circled substructure) of ET-CORMs on toxicity and activity (inhi-
bition of NO-production). The number of arrows indicates the relative
strength of effects.
13868 | Dalton Trans., 2012, 41, 13862–13875 This journal is © The Royal Society of Chemistry 2012
Pu
bl
ish
ed
 o
n 
16
 M
ay
 2
01
2.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
et
sb
ib
lio
th
ek
 R
eg
en
sb
ur
g 
on
 0
1/
08
/2
01
6 
10
:2
5:
58
. 
View Article Online
Overall, rac-13 is considered superior to rac-9 due to its substan-
tially lower cytotoxicity.
Since the (enzyme-triggered) decomposition of the
ET-CORMs not only leads to a release of CO (and the enone
ligand) but also to the liberation of iron ions, the inﬂuence of
Fe2+ and Fe3+ upon the viability and NO-production of
RAW264.7 cells was also assessed. Both FeCl2 and FeCl3
proved to be cytotoxic with IC20 values (viability) of 34 μM for
FeCl2 and 40 μM for FeCl3 together with IC50 values >100 μM
for both compounds (see ESI†). In contrast to other reports,28 no
inﬂuence on the NO-production by Fe2+ and Fe3+ was observed
in the non-toxic concentration range (1 – 25 μM).
Conclusions
We have investigated a series of thirteen acyloxycyclohexa-
diene–Fe(CO)3 complexes as a powerful new class of CO-releas-
ing molecules (ET-CORMs), which are activated by enzymatic
cleavage of the ester functionality. In the course of the study,
new efﬁcient synthetic protocols were developed based on the
use of (stable) triisopropylsilyloxydiene complexes as intermedi-
ates which can be converted into the corresponding esters in a
one-step procedure. The complexes prepared (in racemic form)
were fully characterized and their ability to release CO upon
enzymatic cleavage was investigated in detail. The experimental
results (including the consumption of oxygen) are in accordance
with the proposed CO release mechanism. In biological investi-
gations the cytotoxicity and the inhibition of NO-production (as
an expected consequence of an interaction of CO with iNOS)
was assessed using murine macrophage (RAW264.7) cells.
In the context of the study, clear structure–activity relationships
could be identiﬁed. Two ET-CORMs (rac-9 and rac-13) exhi-
bited particularly promising properties, which to the best of our
knowledge make them the most potent CORMs ever studied in
this type of assay. We also assessed the biological activity of the
expected by-products of the CO release to test whether the bio-
logical activity is solely an effect of CO or a combined effect of
all the “decomposition” products. These experiments revealed
that the enone by-products strongly contribute to the NO-inhi-
bition in the case of the monoesters, but not in the case of the
diesters. The iron ions did not induce signiﬁcant inhibition of the
NO-production in the concentrations tested. The results pre-
sented here suggest that the iron-based ET-CORMs open up
promising options for the future development of small mole-
cules, allowing a controlled and possibly even tissue-selective
CO delivery. A next goal is to ﬁne-tune the pharmacological and
biological properties, for instance by preparing compounds with
higher water solubility.
Experimental
A detailed description of the synthesis of all compounds, includ-
ing the not commercially available starting materials, of all per-
formed CO-detection experiments (including the measured data)
and of the used analytic methods can be found in the ESI.†
NMR spectra were recorded on Bruker instruments (Avance
DPX 300, Avance DRX 500 or Avance II 600). UV/Vis spectra
were recorded on a Beckmann Coulter DU 800 (cell length
1 cm). IR spectra were recorded on a Perkin-Elmer Paragon
1000 FT-IR spectrometer in the ATR mode at room temp-
erature. Mass spectra were recorded at the Central Analytics
Department – Mass Spectroscopy, University of Regensburg and
the Analytical Service Unit, University of Cologne on Finnigan
instruments (a MAT Inocs 50 galaxy system (for EI LR-MS) and
a MAT 900 (for HR-MS)). An Agilent Technologies Model GC
6890N gas chromatograph coupled with an HP 5973N series
mass selective detector and an HP 7683 GC autosampler was
employed for all GC-MS analyses.
Enantiomeric analyses through GC were performed on an
Agilent (HP 6890) instrument with FID detection using either a
BGB-176SE column (A) or a 6TBDMS-2,3-Me-β-CD column
(B). Enantiomeric analyses through high performance liquid
chromatography (HPLC) were conducted with HPLC units from
Merck-Hitachi and Knauer (UV-detection at 220 nm and
254 nm) using one of the following columns: Diacel Chiracel
OD-H (1), Diacel Chiracel OJ (2), Diacel Chiralpak AD-H (3),
Macherey Nagel Nucleocell (4) and n-Hex–i-PrOH (99 : 1, 98 : 2
or 95 : 5) as a solvent. Gas chromatograms for the CO-detection
were recorded using a Varian CP-3800 gas chromatograph with
helium as the carrier gas and a 3 m × 2 mm packed molecular
sieve 13× 80–100 column. The gases were detected using a
thermal conductivity detector (Varian) operated at 150 °C. CHN
analyses were conducted on an Elementar Vario EL machine.
All reactions were carried out in ﬂame-dried glassware under
an argon atmosphere. Chemicals were purchased from Merck,
Sigma-Aldrich, Fluka, Acros, Lancaster or Strem and used
without further puriﬁcation. Solvents were dried following stan-
dard procedures (ESI†). The release of CO via the Mb-assay was
performed as previously described.14
Crystallographic details
Measurements were made on a Nonius Kappa-CCD diffracto-
meter with Mo-Kα radiation (λ = 0.71073), and Denzo was used
for data reduction. The structures were solved by direct methods
(Shelxs97).33 Shelxl97 was used for full-matrix least-squares
reﬁnement on F2. All non-hydrogen atoms were reﬁned aniso-
tropically. All hydrogen atoms were placed in geometrically
idealized positions and reﬁned by using a riding model. Ortep
plots were generated with Platon.34 The absorption correction
(X-RED) was performed after optimizing the crystal shape using
X-SHAPE. Crystal structure determination details are summar-
ized in Table 4.
Detection of the CO release by GC
All reactions were performed in headspace vials – 10 mL (BGB-
analytics, Cat. No. 200410-F). Prior to the detection of the CO
release, a calibration was done using the same solvent mixture
(1 mL of phosphate buffer (0.1 M, pH = 7.4) and 0.2 mL of
DMSO) that was used for the CO release experiments. For the
CO calibration, the consumption of oxygen had to be included.
For this purpose the reaction vial was ﬁlled with the solvent
mixture and completely degassed with nitrogen. Afterwards,
21% of the gas volume was replaced by oxygen to generate the
composition of air (2.250 mL). To generate gas mixtures that are
This journal is © The Royal Society of Chemistry 2012 Dalton Trans., 2012, 41, 13862–13875 | 13869
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formed when a particular amount of O2 is consumed in the
course of the CO release, the volume of added oxygen was
decreased by the amount that is theoretically needed for the
release of the added CO. The resulting gas mixture was warmed
to 37 °C for 10 min prior to the injection and analysis of 50 μL
samples by GC. The determined areas from the GC signals were
plotted against the amount of O2 or CO (calculated with the
ideal gas law) and ﬁtted (linear for 1.0 equiv., 1.5 equiv. and
2.0 equiv. and exponential for 4.0 equiv. and no O2 consump-
tion). Thus, for the CO and O2 calibration, different equivalents
of released CO per consumed O2 were used (1.0 equiv.,
1.5 equiv., 2.0 equiv., 4.0 equiv. and no O2 consumption) and
the calibration data were compared to the experimental data of
the CO release curves. The data for 1.0 equiv., 1.5 equiv. and
2.0 equiv. matched best and were quite similar. Therefore, an
average of the three slopes was taken for the calculation of the
released CO.
To monitor the enzyme-triggered CO release, the particular
complex (36 μmol) was dissolved in DMSO (0.2 mL) and phos-
phate buffer (1 mL; 0.1 M, pH = 7.4) was added. The particular
enzyme (15 mg of PLE or 20 mg of LCR) was added and the
vial was closed with a rubber vial cap. The reaction mixture was
stirred at 37 °C. From time to time samples (50 μL) were taken
and the CO release was quantiﬁed. The half-life times were
determined directly from an exponential ﬁt of the CO-release
(ﬁrst or second order).
Cells and cell culture
The murine macrophage cell line RAW264.735 was kept
under standard cell culture conditions using RPMI with 10%
heat-inactivated fetal calf serum (FCS) and 2 mM glutamine
(Invitrogen, Karlsruhe, Germany).
Determination of cell viability by MTTassay
Cell viability was evaluated by MTT assay as described before.14
In brief, cells were seeded in 96-well plates at a density of
5 × 103 per well, cultured for 24 h, and then incubated for
another 24 h with medium supplemented with compounds and
10 ng mL−1 of LPS (Sigma). Controls received only culture
medium with LPS or with solvent and LPS. Afterwards, super-
natants were removed, 100 μL of MTT solution was added to
each well, and cells were incubated for another 3 h at 37 °C.
Subsequently, 100 μL of SDS-solution (10%) was added, and
formazan was allowed to dissolve overnight. Absorbance was
determined at 560 nm with a multi-well plate photometer
(TiterTek).
Determination of cell proliferation by crystal violet staining
The crystal violet staining was used if it was not possible to get
a reliable result in the MTT test because of interference of the
substances with MTT, and was performed as described pre-
viously.14 In brief, cells were seeded in 96-well plates at a
density of 5 × 103 per well, cultured for 24 h, and then treated
according to the MTT assay. Afterwards, supernatants were
removed and cells were stained with 30 μL crystal violet solution
per well for 10 min. Crystal violet was removed, cells were
washed with 200 μL aqua dest. and allowed to air-dry overnight.
Crystal violet was then solubilized by addition of 100 μL EtOH–
Table 4 Crystal data, data collection and reﬁnement parameters for rac-10, rac-11, rac-12, rac-14, rac-15, rac-17 and rac-18
rac-10 rac-11 rac-12 rac-14 rac-15 rac-17 rac-18
Empirical
formula
C14H16FeO5 C13H14FeO5 C13H14FeO5 C21H28FeO7 C19H24FeO7 C25H38FeO5 C25H38FeO5
M (g mol−1) 320.12 306.09 306.09 448.28 420.23 474.40 474.40
Crystal system Monoclinic Monoclinic Triclinic Triclinic Monoclinic Triclinic Triclinic
Space group P21/c P21/c P1ˉ P1ˉ P21/c P1ˉ P1ˉ
a (Å) 12.4124(4) 9.6264(7) 6.1260(4) 11.0195(8) 13.5179(16) 8.6905(3) 6.6635(14)
b (Å) 6.4417(2) 14.1259(7) 7.5018(5) 13.4293(8) 12.1754(7) 10.0025(4) 6.7003(15)
c (Å) 18.6015(7) 11.9873(7) 15.0179(10) 16.2464(10) 12.5175(15) 28.6690(12) 28.213(6)
α (°) 90 90 77.693(4) 75.189(4) 90 89.975(2) 85.849(5)
β (°) 104.644(2) 124.757(4) 89.267(3) 86.972(3) 100.201(3) 87.653(2) 86.939(6)
γ (°) 90 90 78.463(3) 89.571(3) 90 82.287(2) 82.030(7)
V (Å3) 1439.00(8) 1339.21(16) 660.36(8) 2321.0(3) 2027.6(4) 2467.45(17) 1243.0(5)
T (K) 100(2) 100(2) 100(2) 150(2) 100(2) 100(2) 100(2)
Z 4 4 2 4 4 4 2
Dc (g cm
−3) 1.478 1.518 1.539 1.283 1.377 1.277 1.268
Crystal size
(mm3)
0.2 × 0.15 ×
0.07
0.2 × 0.07 ×
0.02
0.2 × 0.2 × 0.07 0.2 × 0.2 × 0.1 0.1 × 0.07 ×
0.02
0.15 × 0.05 ×
0.01
0.3 × 0.1 × 0.03
θ range (°) 1.70 to 26.99 2.52 to 26.99 1.39 to 26.99 1.30 to 27.00 1.53 to 25.00 1.42 to 27.00 1.45 to 25.00
No. data
collected
13 203 6848 4112 15 189 12 099 16 558 5290
No. unique data 3140 2918 2877 10 119 3374 10 724 4158
Final R indices
[I > 2σ(I)]
R1 = 0.0285,
wR2 = 0.0734
R1 = 0.0322,
wR2 = 0.0734
R1 = 0.0233,
wR2 = 0.0572
R1 = 0.0667,
wR2 = 0.1514
R1 = 0.0606,
wR2 = 0.1592
R1 = 0.0579,
wR2 = 0.1363
R1 = 0.0745,
wR2 = 0.1718
R indices
(all data)
R1 = 0.0358,
wR2 = 0.0756
R1 = 0.0540,
wR2 = 0.0800
R1 = 0.0277,
wR2 = 0.0627
R1 = 0.1565,
wR2 = 0.1848
R1 = 0.0916,
wR2 = 0.1803
R1 = 0.0986,
wR2 = 0.1561
R1 = 0.1435,
wR2 = 0.2007
Largest diff.
peak/hole
(e Å−3)
0.452/−0.374 0.533/−0.466 0.360/−0.261 0.560/−0.420 1.017/−0.510 1.027/−0.670 1.091/−0.413
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Na-citrate solution per well and absorbance was determined at
560 nm.
Measurement of nitrite production by Griess assay
Generation of NO was determined by the Griess reaction which
is based on the detection of accumulating nitrite in the cell
culture medium.36 The assay was performed as described pre-
viously.14 Brieﬂy, cells were seeded in 96-well plates at a density
of 8 × 104 per well, cultured for 24 h and subsequently incubated
for another 24 h with medium supplemented with compounds
and 10 ng mL−1 of LPS. Afterwards a volume of 100 μL culture
supernatant was mixed with 100 μL of Griess reagent. After
15 min incubation at room temperature, absorbance was deter-
mined at 560 nm. The nitrite content was determined by using
sodium nitrite as the standard.
Data evaluation/statistical analysis
Experiments were carried out with at least four parallels and
repeated independently at least three times. Results are expressed
as mean ± SD and are depicted as a percentage of untreated con-
trols. A sigmoidal logistic function was used to ﬁt dose–response
curves and to determine IC50 and IC20 values, using a Microsoft
Excel calculation sheet (Ed50plus, v1.0, April 2000,
Mario H. Vargas, Instituto Nacional de Enfermedades, Mexico).
Statistical analysis was performed using the software Prism
(GraphPad Software). Quantitative data were tested with a two-
tailed paired Student’s t-test referring to the untreated control.
Levels of signiﬁcance: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
Syntheses
Synthesis of the γ-pivalate substituted enones 28 and 29. A
solution of cyclohexa-1,3-dione (1.0 equiv.) and pyridine
(2.0 equiv.) in DCM was cooled to 0 °C. Pivaloyl chloride
(1.5 equiv.) was added dropwise and the reaction mixture was
stirred (1 h). Afterwards water was added, the phases were sepa-
rated and the aqueous phase was extracted with DCM. The com-
bined organic phases were dried over anhydrous MgSO4, the
solvent was evaporated and the raw product was puriﬁed by
column chromatography.
3-Oxocyclohex-1-en-1-yl pivalate (28). Yield: 11.5 g
(29.2 mmol, 82%). FT-IR (ATR): ν [cm−1] = 2971 (m, Csp3–H),
2874 (m, Csp3–H), 1748 (s, CvO).
1H NMR (300 MHz,
CDCl3): δ = 5.80 (s, 1H, H2), 2.46 (t, J = 6.1 Hz, 2H, H4), 2.35
(t, J = 6.7 Hz, 2H, H6), 2.08–1.93 (Ψq, J = 6.4 Hz, 2H, H5),
1.22 (s, 9H, H9). 13C NMR (75 MHz, CDCl3): δ = 199.4 (C3),
175.1 (C7), 170.3 (C1), 117.4 (C2), 39.2 (C8), 36.6 (C4),
28.1 (C6), 26.8 (C9), 21.2 (C5). LR-MS (GC-MS): m/z (%) =
196 (1, [M]+), 153 (3), 125 (4), 113 (35), 96 (4), 85 (71),
83 (43), 69 (21), 57 (100).
5,5-Dimethyl-3-oxocyclohex-1-en-1-yl pivalate (29). Yield:
14.37 g (68.04 mmol, 90%). mp < 30 °C (from DCM). FT-IR
(ATR): ν [cm−1] = 2966 (w, Csp3–H), 2866 (w, Csp3–H), 1754
(m, CvO). 1H NMR (300 MHz, CDCl3): δ = 5.86 (s, 1H, H2),
2.40 (s, 2H, H4), 2.27 (s, 2H, H6), 1.28 (s, 9H, H11), 1.12 (s,
6H, H7, H8). 13C NMR (75 MHz, CDCl3): δ = 199.3 (C3),
175.4 (C9), 168.7 (C1), 116.6 (C2), 50.8 (C4), 42.0 (C6),
39.3 (C10), 33.1 (C5), 28.2 (C11), 26.9 (C7, C8). GC-MS:
m/z (%) = 224 (<1, [M]+), 181 (4), 141 (66, [M − C5H7O]+),
112 (10), 85 (100), 57 (100), 41 (50).
General procedure 1 for dienyl-ester and silyldienol ether
formation
To a solution of diisopropylamine (ca. 1.5 equiv.) in THF was
added n-butyllithium (ca. 1.3 equiv.) at −78 °C. After stirring
the mixture for 10 min, a solution of the particular enone
(1 equiv.) in THF was added dropwise (ca. 1 h). Stirring was
continued for 1 h at −78 °C. Afterwards the particular electro-
phile (2.5 equiv., 1.2 equiv. for TIPSOTf) in THF was added
dropwise (1 h). After 30 min at −78 °C the reaction mixture was
allowed to warm to 25 °C before it was quenched by addition of
saturated aqueous NH4Cl. After 10 min the mixture was
extracted with MtBE and the organic layer was washed with
water and brine and dried over anhydrous MgSO4. Finally, the
solvent was evaporated and the crude product was puriﬁed by
column chromatography.
4,4-Dimethylcyclohexa-1,5-dien-1-yl acetate (22). Yield:
1.49 g (8.8 mmol, 70%). FT-IR (ATR): ν [cm−1] = 3017
(w, Csp2–H), 2957 (s, Csp3–H), 2866 (m, Csp3–H), 2819
(w, Csp3–H), 1759 (s, CvO).
1H NMR (300 MHz, CDCl3): δ =
5.55 (m, 2H, H6, H5), 5.24 (m, 1H, H2), 2.19 (d, J = 1.0 Hz,
2H, H3), 2.09 (s, 3H, H9), 1.01 (s, 6H, H7). 13C NMR
(75 MHz, CDCl3): δ = 169.2 (C8), 145.0 (C1), 140.0 (C5),
120.4 (C6), 109.8 (C2), 36.5 (C3), 31.2 (C4), 27.6 (C7),
20.9 (C9). LR-MS (GC-MS): m/z (%) = 166 (20, [M]+), 124
(46), 109 (100), 91 (15), 81 (15), 67 (8), 55 (10), 43 (14).
3,3-Dimethylcyclohexa-1,5-dien-1-yl acetate (24). Yield:
1.361 g (8.1 mmol, 65%). FT-IR (ATR): ν [cm−1] = 2955 (m,
Csp3–H), 2923 (m, Csp3–H), 2865 (w, Csp3–H), 1759 (s, CvO).
1H NMR (300 MHz, CDCl3): δ = 5.83–5.74 (m, 1H, H6), 5.66
(ddd, J = 9.9, 3.7, 1.9 Hz, 1H, H5), 5.10 (Ψd, J = 1.7 Hz, 1H,
H2), 2.12 (Ψdd, J = 4.3, 1.9 Hz, 2H, H4), 2.10 (s, 3H, H8), 1.02
(s, 6H, H9, H10). 13C NMR (75 MHz, CDCl3): δ = 169.2 (C7),
144.4 (C1), 127.7 (C6), 122.0 (C5), 121.9 (C2), 37.5 (C4),
31.7 (C3), 28.1 (C9, C10), 21.0 (C8). LR-MS (GC-MS):
m/z (%) = 166 (9, [M]+), 124 (10, [M − (CH2CO)]+), 109 (100),
91 (9), 79 (10), 68 (8), 43 (20).
Cyclohexa-1,3-diene-1,3-diyl dipivalate (30). Yield: raw
product containing ca. 583 mg (2.08 mmol, 40%). FT-IR (ATR):
ν [cm−1] = 2971 (m, Csp3–H), 2880 (w, Csp3–H), 1747 (s,
CvO). 1H NMR (300 MHz, CDCl3): δ = 5.50 (s, 1H, H2), 5.26
(s, 1H, H4), 2.59–2.23 (m, 4H, H5, H6), 1.25 (s, 18H, H9,
H12). 13C NMR (75 MHz, CDCl3): δ = 176.9 (C7/C10),
176.3 (C7/C10), 151.0 (C1/C3), 144.9 (C1/C3), 110.0 (C2),
107.7 (C4), 39.0 (C8/C11), 38.8 (C8/C11), 27.0 (C9, C12),
25.3 (C6), 21.6 (C5). LR-MS (GC-MS): m/z (%) = 280 (4,
[M]+), 196 (10), 112 (39), 85 (10), 68 (25), 57 (100), 41 (61).
5,5-Dimethylcyclohexa-1,3-diene-1,3-diyl dipivalate (31). Yield:
1.77 g (5.8 mmol, 46%). mp < 30 °C (from DCM). FT-IR
(ATR): ν [cm−1] = 2965 (m, Csp3–H), 2866 (w, Csp3–H),
This journal is © The Royal Society of Chemistry 2012 Dalton Trans., 2012, 41, 13862–13875 | 13871
Pu
bl
ish
ed
 o
n 
16
 M
ay
 2
01
2.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
et
sb
ib
lio
th
ek
 R
eg
en
sb
ur
g 
on
 0
1/
08
/2
01
6 
10
:2
5:
58
. 
View Article Online
1747 (s, CvO). 1H NMR (300 MHz, CDCl3): δ = 5.49 (s, 1H,
H2), 5.06 (Ψd, J = 1.2 Hz, 1H, H6), 2.28 (s, 2H, H4), 1.25 (s,
18H, H11, H14), 1.14 (s, 6H, H7, H8). 13C NMR (75 MHz,
CDCl3): δ = 176.9 (C9/C12), 176.6 (C9/C12), 150.4 (C1/C3),
143.2 (C1/C3), 119.1 (C2), 109.1 (C6), 40.3 (C4), 39.0
(C10/C13), 38.8 (C10/C13), 33.2 (C5), 28.3 (C7, C8), 27.0
(C11, C14). GC-MS: m/z (%) = 308 (8, [M]+), 224 (11,
[M − C5H8O]+), 209 (25), 140 (7), 125 (41), 109 (4), 85 (8),
57 (100), 41 (36).
(Cyclohexa-1,5-dien-1-yloxy)triisopropylsilane (33). Yield:
3.77 g (15.5 mmol, 99%). FT-IR (ATR): ν [cm−1] = 3020 (w,
Csp2–H), 2940 (s, Csp3–H), 2860 (s, Csp3–H), 1700 (m), 1646
(s). 1H NMR (300 MHz, CDCl3): δ = 5.87–5.83 (m, 1H, H5),
5.76–5.72 (d, J = 6.0 Hz, 1H, H6), 4.89 (Ψs, 1H, H2),
2.14–2.07 (m, 4H, H3, H4), 1.17–1.10 (d, J = 1.1 Hz, 18H, H8),
1.07–1.05 (m, 3H, H7). 13C NMR (75 MHz, CDCl3): δ = 148.6
(C1), 128.7 (C5), 126.7 (C6), 101.9 (C2), 22.6–21.8 (C3/C4),
17.9 (C8), 12.5 (C7). LR-MS (GC-MS): m/z (%) = 252 (100,
[M]+), 237 (1), 209 (30), 179 (50), 151 (83), 121 (16), 103 (11),
75 (36), 59 (35), 41 (28). HR-MS (DIP-MS, 70 eV): m/z
252.191 (calcd ([M]+) m/z 252.1909).
General procedure 2 for dienyl-ester and silyldienol ether
formation
To a solution of hexamethyldisilazane (1.5 equiv.) in THF was
added n-butyllithium (1.3 equiv.) at −78 °C. After 10 min TPPA
(2.5 equiv.) was added and stirring was continued for 20 min at
−78 °C. Then the particular enone (1.0 equiv.) in THF was
added dropwise (1 h). Afterwards the particular electrophile
(2.5 equiv., 1.2 equiv. for TIPSOTf) in THF was added dropwise
(1 h). The mixture was stirred for an additional 30 min at
−78 °C and then allowed to warm to 25 °C before it was
quenched with saturated aqueous NH4Cl. After extraction with
MtBE, the organic solution was washed with water and brine
and dried over anhydrous MgSO4. Finally, the solvent was
evaporated and the crude product was puriﬁed by column
chromatography.
Cyclohexa-1,3-dienyl pivalate (20). Yield: 900 mg (5.0 mmol,
62%). FT-IR (ATR): ν [cm−1] = 2968 (w, Csp3–H), 2933 (s,
Csp3–H), 2871 (m, Csp3–H), 1741 (s, CvO).
1H NMR
(500 MHz, CDCl3): δ = 5.94–5.77 (m, 1H, H3), 5.70–5.51 (m,
2H, H2, H4), 2.43–2.21 (m, 4H, H5, H6), 1.23 (s, 9H, H9).
13C NMR (125 MHz, CDCl3): δ = 176.7 (C7), 149.4 (C1),
123.3 (C3/C4), 122.9 (C3/C4), 110.6 (C2), 38.9 (C8), 27.0 (C9),
25.3 (C5/C6), 23.6 (C5/C6). LR-MS (GC-MS): m/z (%) =
180 (10, [M]+), 96 (98), 79 (12), 67 (15), 57 (100, [C(CH3)3]
+),
41 (47).
(Cyclohexa-1,3-dien-1-yloxy)triisopropylsilane (37). Yield:
1.90 g (7.5 mmol, 85%). FT-IR (ATR): ν [cm−1] = 3039 (w,
Csp2–H), 2941 (s, Csp3–H), 2889 (m, Csp3–H), 2864 (s, Csp3–H).
1H NMR (300 MHz, CDCl3): δ = 5.94–5.69 (m, 1H, H3), 5.39
(Ψdd, J = 9.2, 3.8 Hz, 1H, H4), 5.12 (d, J = 5.8 Hz, 1H, H2),
2.25 (Ψd, J = 12.0 Hz, 4H, H5, H6), 1.24–1.15 (m, 3H, H7),
1.10 (s, 12H, H8), 1.08 (s, 6H, H8). 13C NMR (75 MHz,
CDCl3): δ = 154.1 (C1), 124.7 (C3), 117.8 (C4), 101.7 (C2),
28.7 (C5/C6), 24.0 (C5/C6), 17.9 (C7), 12.6 (C8). LR-MS
(GC-MS): m/z (%) = 252 (90, [M]+), 207 (59), 179 (59),
151 (100), 137 (71), 121 (23), 77 (37), 59 (26), 41 (23).
5,5-Dimethylcyclohexa-1,3-dien-1-yl acetate (25). Yield:
881 mg (5.3 mmol, 65%). FT-IR (ATR): ν [cm−1] = 2946 (m,
Csp3–H), 2920 (s, Csp3–H), 2851 (m, Csp3–H), 1756 (s, CvO).
1H NMR (300 MHz, CDCl3): δ = 5.70 (dd, J = 9.4, 5.8 Hz, 1H,
H3), 5.57 (d, J = 5.8 Hz, 1H, H4), 5.37 (d, J = 9.4 Hz, 1H, H2),
2.22 (Ψd, J = 1.1 Hz, 2H, H6), 2.11 (s, 3H, H8), 1.04 (s, 6H,
H9, H10). 13C NMR (75 MHz, CDCl3): δ = 169.0 (C7), 148.7
(C1), 135.2 (C2), 119.8 (C3), 109.6 (C4), 40.3 (C6), 33.8 (C5),
27.9 (C9, C10), 21.0 (C8). LR-MS (GC-MS): m/z (%) = 166
(17, [M]+), 124 (26, [M − (CH2CO)]+), 109 (100), 91 (9),
79 (10), 43 (25).
General preparation of diene–Fe(CO)3 complexes
A Schlenk tube was charged with the diene (1 equiv.) and
Fe2(CO)9 (2–3 equiv.) and set under argon by three evacuation/
argon ﬂush cycles. Then, degassed diethyl ether was added and
the reaction mixture was heated to reﬂux for 20 h under argon.
Finally, the solvent was evaporated and the crude mixture was
puriﬁed by column chromatography to yield the desired
complex.
(RS)-Tricarbonyl-η4-(1-hexadecanoyloxy-1,5-cyclohexadiene)-
iron(0) (rac-17). Without column chromatography, the solvent
was evaporated, the residue was dissolved in DMF and the solu-
tion was added to NaH (3.7 equiv.). The reaction mixture was
cooled (0 °C) and TBAF (1.8 equiv.) was added dropwise. After
45 min palmitoyl chloride (2.0 equiv.) was added and the reac-
tion was stirred at 20 °C (3 h, TLC). After workup and puriﬁ-
cation by column chromatography (DCM–CyHex = 1 : 3),
986 mg (2.08 mmol, 62%) of complex rac-17 were isolated as a
yellow solid. mp 36.7 °C (DCM). EA: Calcd for C25H38FeO5:
C 63.29; H 8.07. Found: C 62.81; H 8.15. FT-IR (ATR): ν
[cm−1] = 2921 (s, Csp3–H), 2851 (m, Csp3–H), 2045 (s,
Fe(CO)3), 1967 (bs, Fe(CO)3), 1762 (m, CvO).
1H NMR
(500 MHz, CDCl3): δ = 5.53 (Ψdd, J = 6.6, 1.2 Hz, 1H, H6),
3.38 (Ψdt, J = 3.8, 2.2 Hz, 1H, H2), 2.88 (dt, J = 6.4, 2.9 Hz,
1H, H5), 2.45 (t, J = 7.5 Hz, 2H, H8), 1.91–1.74 (m, 2H, H3),
1.73–1.65 (m, 2H, H21), 1.62–1.54 (m, 2H, H4), 1.41–1.25 (m,
24H, H9–H20), 0.90 (t, J = 7.0 Hz, 3H, H22). 13C NMR
(126 MHz, CDCl3): δ = 210.5 (Fe(CO)3), 173.0 (C7), 128.1
(C1), 79.4 (C6), 58.9 (C2), 51.7 (C5), 33.9 (C8), 31.7 (C9–
C20), 29.4 (C9–C20), 29.4 (C9–C20), 29.4 (C9–C20), 29.3
(C9–C20), 29.2 (C9–C20), 29.1 (C9–C20), 28.9 (C9–C20), 28.7
(C9–C20), 24.7 (C3/C21), 24.5 (C3/C21), 23.2 (C4), 22.4 (C9–
C20), 13.9 (C22). LR-MS (DIP-MS, 70 eV): m/z (%) = 446 (1,
[M − CO]+), 418 (5, [M − 2CO]+), 390 (100, [M − 3CO]+), 310
(29), 309 (35), 226 (34), 212 (56), 198 (39), 184 (25), 170 (19),
156 (17), 151 (40), 97 (36), 83 (28), 71 (37), 57 (87), 56 (46,
[Fe]+). HR-MS (DIP-MS, 70 eV): m/z 418.217 ± 0.0021 (calcd
([M − 2CO]+): m/z 418.2170).
(RS)-Tricarbonyl-η4-(1-triisopropylsiloxy-1,3-cyclohexadiene)-
iron(0) (rac-38). Yield: 1.38 g (3.51 mmol, 89%). FT-IR (ATR):
ν [cm−1] = 2942 (s, Csp3–H), 2889 (m, Csp3–H), 2865 (s, Csp3–
H), 2031 (s, Fe(CO)3), 1948 (bs, Fe(CO)3).
1H NMR (300 MHz,
CDCl3): δ = 5.18 (d, J = 4.3 Hz, 1H, H2), 5.94 (Ψt, J = 9.0 Hz,
13872 | Dalton Trans., 2012, 41, 13862–13875 This journal is © The Royal Society of Chemistry 2012
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1H, H3), 2.89–2.78 (m, 1H, H4), 2.28–2.10 (m, 1H, H6),
2.06–1.81 (m, 2H, H5, H6), 1.68–1.75 (m, 1H, H5), 1.09 (s,
21H, H7, H8). 13C NMR (75 MHz, CDCl3): δ 213.3 (Fe(CO)3),
113.9 (C1), 78.1 (C2), 76.0 (C3), 56.7 (C4), 31.0 (C6), 24.6
(C5), 18.0 (C8), 13.2 (C7). LR-MS (DIP-MS, 70 eV): m/z (%) =
392 (1, [M]+), 364 (32, [M − CO]+), 336 (9, [M − 2CO]+),
334 (25), 308 (7, [M − 3CO]+), 306 (95), 290 (15), 265 (17),
264 (100), 252 (16), 248 (21), 222 (33), 207 (15), 179 (15),
164 (11), 151 (20), 137 (17), 121 (5), 100 (5). HR-MS
(DIP-MS, 70 eV): m/z 364.116 (calcd ([M − CO]+): m/z
364.1157).
(RS)-Tricarbonyl-η4-(1-triisopropylsiloxy-1,5-cyclohexadiene)-
iron(0) (rac-35). Yield: 2.85 g (7.28 mmol, 92%). FT-IR (ATR):
ν [cm−1] = 2944 (s, Csp3–H), 2889 (m, Csp3–H), 2865 (s, Csp3–
H), 2040 (s, Fe(CO)3), 1960 (bs, Fe(CO)3).
1H NMR (300 MHz,
CDCl3): δ = 5.28 (d, J = 6.5 Hz, 1H, H6), 3.39 (Ψs, 1H, H2),
2.70 (d, J = 2.7 Hz, 1H, H6), 1.84–1.62 (m, 2H, H3),
1.48 (Ψddd, J = 19.3, 14.4, 9.0 Hz, 2H, H4), 1.22 (Ψdd, J =
14.4, 6.9 Hz, 3H, H7), 1.11 (s, 18H, H8). 13C NMR (75 MHz,
CDCl3): δ = 211.6 (Fe(CO)3), 136.5 (C1), 76.7 (C6), 58.6 (C2),
50.5 (C5), 25.4 (C3), 23.1 (C4), 17.7 (C8), 12.4 (C7). LR-MS
(DIP-MS, 70 eV): m/z (%) = 392 (2, [M]+), 364 (31, [M −
CO]+), 336 (9, [M − 2CO]+), 334 (30), 308 (14, [M − 3CO]+),
306 (100), 290 (30), 265 (17), 264 (98), 252 (5), 248 (19), 222
(45), 207 (15), 179 (15), 164 (25), 151 (10), 137 (15), 121 (9),
100 (5). HR-MS (DIP-MS, 70 eV): m/z 364.115 ± 0.0004 (calcd
([M − CO]+): m/z 364.1157).
(RS)-Tricarbonyl-η4-(1-hexadecanoyloxy-1,3-cyclohexadiene)-
iron(0) (rac-18). A solution of TBAF (2.5 mL, 3.00 mmol,
1.2 M in THF, 3.5 equiv.) was added to a solution of complex
rac-38 (333 mg, 0.85 mmol, 1 equiv.) in DMF (10 mL) and the
mixture was stirred (10 min, TLC). Afterwards DIPEA
(0.51 mL, 3.0 mmol, 3.5 equiv.) was added, followed by the
addition of palmitoyl chloride (0.91 mL, 3.0 mmol, 3.5 equiv.).
After stirring at 20 °C to completion (10 min, TLC), the reaction
was quenched by the addition of water and extracted with
hexane and MtBE. The combined organic solvents were dried
over MgSO4 and evaporated. After puriﬁcation by column
chromatography (DCM–CyHex = 1 : 3), 393 mg (0.83 mmol,
97%) of complex rac-18 were isolated as a yellow solid. mp
29.5 °C (from DCM). EA: Calcd for C25H38FeO5: C 63.29;
H 8.07. Found: C 63.45; H 8.08. FT-IR (ATR): ν [cm−1] = 2920
(s, Csp3–H), 2850 (s, Csp3–H), 2046 (s, Fe(CO)3), 1962 (bs,
Fe(CO)3), 1748 (s, CvO).
1H NMR (500 MHz, CDCl3): δ =
5.39 (d, J = 4.3 Hz, 1H, H2), 5.21–5.06 (m, 1H, H3), 3.11 (ddd,
J = 5.5, 3.8, 1.8 Hz, 1H, H4), 2.32 (t, J = 7.6 Hz, 2H, H8), 2.17
(ddd, J = 12.6, 3.0, 1.6 Hz, 1H, H6), 1.89 (ddt, J = 15.0, 11.6,
3.4 Hz, 1H, H5), 1.84–1.75 (m, 1H, H6), 1.75–1.66 (m, 1H,
H6), 1.63 (dd, J = 14.2, 7.3 Hz, 2H, H21), 1.36–1.23 (m, 24H,
H9–H20), 0.90 (t, J = 6.9 Hz, 3H, H22). 13C NMR (126 MHz,
CDCl3): δ = 211.3 (Fe(CO)3), 172.0 (C7), 103.2 (C1), 80.5
(C3), 80.3 (C2), 60.2 (C4), 34.5 (C8), 31.9 (C9–C20), 29.7 (C9–
C20), 29.7 (C9–C20), 29.6 (C9–C20), 29.6 (C9–C20), 29.4
(C9–C20), 29.4 (C9–C20), 29.2 (C9–C20), 29.0 (C9–C20), 26.7
(C6), 24.8 (C21), 24.0 (C5), 22.7 (C9–C20), 14.1 (C22).
LR-MS (DIP-MS, 70 eV): m/z (%) = 446 (2, [M − CO]+),
418 (6, [M − 2CO]+), 390 (100, [M − 3CO]+), 362 (4), 334 (6),
310 (17), 309 (28), 254 (18), 240 (22), 198 (15), 156 (8), 149
(21), 134 (14), 97 (12), 96 (40), 57 (33), 56 (22, [Fe]+). HR-MS
(DIP-MS, 70 eV): m/z 446.2115 ± 0.0004 (calcd ([M − CO]+):
m/z 446.2119).
(RS)-Tricarbonyl-η4-(1-acetoxy-3,3-dimethyl-1,5-cyclohexadiene)-
iron(0) (rac-12). Yield: 525 mg (1.72 mmol, 57%). mp 54.1 °C
(from DCM). EA: Calcd for C13H14FeO5: C 51.01; H 4.61.
Found: C 51.00; H 4.65. FT-IR (ATR): ν [cm−1] = 2953 (m,
Csp3–H), 2866 (w, Csp3–H), 2043 (s, Fe(CO)3), 1961 (bs,
Fe(CO)3), 1767 (s, CvO).
1H NMR (600 MHz, CDCl3): δ =
5.62 (d, J = 6.0 Hz, 1H, H6), 3.07 (Ψd, J = 2.0 Hz, 1H, H2),
2.75–2.72 (m, 1H, H5), 2.17 (s, 3H, H8), 1.56–1.41 (m, 2H,
H4), 1.08 (s, 3H, H9/H10), 1.03 (s, 3H, H9/H10). 13C NMR
(150 MHz, CDCl3): δ = 211.0 (Fe(CO)3), 169.7 (C7), 126.6
(C1), 81.1 (C6), 71.1 (C2), 51.4 (C5), 42.1 (C4), 36.1 (C3), 34.6
(C9/C10), 30.8 (C9/C10), 21.2 (C8). LR-MS (DIP-MS, 70 eV):
m/z (%) = 278 (12, [M − CO]+), 250 (26, [M − 2CO]+), 222
(24, [M − 3CO]+), 206 (100), 178 (12), 164 (19), 146 (9), 134
(10), 109 (17), 97 (24), 91 (14), 71 (8), 68 (12), 56 (57, [Fe]+).
HR-MS (DIP-MS, 70 eV): m/z 278.0145 ± 0.0004 (calcd
([M − CO]+): m/z 278.0241).
(RS)-Tricarbonyl-η4-(1-acetoxy-4,4-dimethyl-1,5-cyclohexadiene)-
iron(0) (rac-11). Yield: 659 mg (2.15 mmol, 72%). mp 44.7 °C
(from DCM). EA: Calcd for C13H14FeO5: C 51.01; H 4.61.
Found: C 51.27; H 4.69. FT-IR (ATR): ν [cm−1] = 2995 (m,
Csp3–H), 2859 (w, Csp3–H), 2043 (s, (Fe(CO)3), 1967 (bs,
Fe(CO)3), 1762 (s, CvO).
1H NMR (500 MHz, CDCl3): δ =
5.45 (Ψdd, J = 1.9, 6.6 Hz, 1H, H6), 3.20 (dd, J = 2.7, 4.9 Hz,
1H, H2), 2.50 (d, J = 6.3 Hz, 1H, H5), 2.18 (s, 3H, H10),
1.78 (dd, J = 2.8, 14.9 Hz, 1H, H3), 1.6 (dd, J = 3.0, 14.9 Hz,
1H, H3), 1.00 (s, 3H, H7/H8), 0.96 (s, 3H, H7/H8). 13C NMR
(125 MHz, CDCl3): δ = 210.9 (Fe(CO)3), 170.2 (C9), 128.8
(C1), 76.7 (C6), 65.1 (C5), 58.2 (C2), 43.0 (C3), 34.7 (C4),
34.2 (C7/C8), 30.7 (C7/C8), 21.0 (C9). LR-MS (DIP-MS,
70 eV): m/z (%) = 278 (5, [M − CO]+), 250 (15, [M − 2CO]+),
222 (3, [M − 3CO]+), 206 (100), 178 (12), 164 (20), 146 (11),
134 (9), 119 (10), 109 (17), 97 (24), 91 (20), 83 (28), 71 (43),
69 (43), 57 (81), 56 (57, [Fe]+). HR-MS (DIP-MS, 70 eV): m/z
278.024 ± 0.0011 (calcd ([M − CO]+): m/z 278.0241).
(RS)-Tricarbonyl-η4-(1-acetoxy-5,5-dimethyl-1,3-cyclohexadiene)-
iron(0) (rac-13). Yield: 525 mg (1.72 mmol, 57%). EA: Calcd
for C13H14FeO5: C 51.01; H 4.61. Found: C 50.81; H 4.94.
FT-IR (ATR): ν [cm−1] = 2957 (m, Csp3–H), 2860 (w, Csp3–H),
2044 (s, Fe(CO)3), 1962 (bs, Fe(CO)3), 1752 (s, CvO).
1H NMR (500 MHz, CDCl3): δ = 5.40–5.35 (m, 1H, H2),
5.07 (dd, J = 4.5, 6.5 Hz, 1H, H3), 2.76 (Ψdd, J = 1.0, 6.5 Hz,
1H, H4), 2.20–2.10 (m, 1H, H6), 2.02 (s, 3H, H8), 1.76–1.70
(m, 1H, H6), 1.09 (s, 3H, H9/H10), 0.96 (s, 3H, H9/H10).
13C NMR (125 MHz, CDCl3): δ = 169.7 (C7), 101.9 (C1), 81.3
(C2), 77.4 (C3), 72.6 (C4), 44.9 (C6), 34.9 (C9/C10), 30.9
(C9/C10), 20.9 (C8). LR-MS (DIP-MS, 70 eV): m/z (%) = 306
(1, [M]+), 278 (12, [M − CO]+), 250 (36, [M − 2CO]+), 222
(29, [M − 3CO]+), 206 (100), 178 (12), 164 (15), 146 (11), 134
(9), 119 (10), 91 (11), 83 (28), 71 (9), 56 (26, [Fe]+). HR-MS
(DIP-MS, 70 eV): m/z 278.021 ± 0.0001 (calcd ([M − CO]+):
m/z 278.0241).
This journal is © The Royal Society of Chemistry 2012 Dalton Trans., 2012, 41, 13862–13875 | 13873
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(RS)-Tricarbonyl-η4-(1-(2,2-dimethylpropanoyloxy)-1,3-cyclo-
hexadiene)iron(0) (rac-10). Yield: 895 mg (2.79 mmol, 72%).
mp 50.5 °C (from DCM). EA: Calcd for C14H16FeO5: C 52.53;
H 5.04. Found: C 52.36; H 5.05. FT-IR (ATR): ν [cm−1] = 2931
(s, Csp3–H), 2859 (m, Csp3–H), 2047 (s, Fe(CO)3), 1970 (bs,
Fe(CO)3), 1739 (s, CvO).
1H NMR (500 MHz, CDCl3): δ = 5.39
(d, J = 4.0 Hz, 1H, H2), 5.13 (Ψt, J = 5.5 Hz, 1H, H3), 3.13–3.08
(m, 1H, H4), 2.18–2.09 (m, 1H, H5/H6), 1.92–1.85 (m, 1H, H5/
H6), 1.81–1.74 (m, 1H, H5/H6), 1.74–1.64 (m, 1H, H5/H6), 1.22
(s, 9H, H9). 13C NMR (125 MHz, CDCl3): δ = 211.4 (Fe(CO)3),
176.7 (C7), 103.4 (C1), 80.4 (C2/C3), 80.3 (C2/C3), 60.2 (C4),
38.9 (C8), 27.0 (C9), 26.5 (C5/C6), 24.0 (C5/C6). LR-MS
(DIP-MS, 70 eV): m/z (%) = 292 (8, [M − CO]+), 264 (49, [M −
2CO]+), 236 (44, [M − 3CO]+), 234 (100), 180 (1), 150 (1), 134
(12), 96 (2), 57 (3, [C(CH3)3]
+). HR-MS (DIP-MS, 70 eV): m/z
292.040 ± 0.0002 (calcd ([M − CO]+): m/z 292.0398).
(RS)-Tricarbonyl-η4-(1,3-di-(2,2-dimethylpropanoyloxy)-1,3-
cyclohexadiene)iron(0) (rac-15). Yield: 899 mg (2.14 mmol,
67%). mp 58.3 °C (from DCM). EA: Calcd for C19H24FeO7:
C 54.30; H 5.76. Found: C 54.46; H 5.78. FT-IR (ATR): ν
[cm−1] = 2974 (m, Csp3–H), 2926 (m, Csp3–H), 2900 (w, Csp3–
H), 2052 (s, Fe(CO)3), 1979 (bs, Fe(CO)3), 1753 (s, CvO),
1740 (s, CvO). 1H NMR (600 MHz, CDCl3): δ = 5.72–5.55
(m, 1H, H2), 3.26–3.25 (m, 1H, H4), 2.12–1.93 (m, 1H, H6),
1.84–1.81 (m, 2H, H5), 1.69–1.62 (m, 1H, H6), 1.23 (s, 9H, H9/
H12), 1.17 (s, 9H, H9/H12). 13C NMR (150 MHz, CDCl3): δ =
177.7 (C7/C10), 176.7 (C7/C10), 124.1 (C3), 94.9 (C1), 74.9
(C2), 57.1 (C4), 39.1 (C8/C11), 39.0 (C8/C11), 27.0 (C9/C12),
26.9 (C9/C12), 26.2 (C6), 23.6 (C5). LR-MS (DIP-MS, 70 eV):
m/z (%) = 364 (6, [M − CO]+), 336 (40, [M − 2CO]+), 308 (6,
[M − 3CO]+), 293 (10), 266 (5), 252 (41), 224 (38), 196 (15),
168 (17), 165 (27), 138 (6), 122 (4), 112 (7), 85 (10), 57 (100),
56 (17, [Fe]+). HR-MS (DIP-MS, 70 eV): m/z 364.097 ± 0.004
(calcd ([M − CO]+): m/z 364.0973).
(RS)-Tricarbonyl-η4-(1,3-di(2,2-dimethylpropanoyloxy)-5,5-
dimethyl-1,3-cyclohexadiene)iron(0) (rac-14). Yield: 1.23 g
(1.89 mmol, 77%). mp 38.4 °C (from DCM). EA: Calcd for
C21H28FeO7: C = 56.26, H = 6.30. Found: C = 56.56, H = 6.26.
FT-IR (ATR): ν [cm−1] = 2970 (m, Csp3–H), 2860 (w, Csp3–H),
2050 (s, Fe(CO)3), 1970 (bs, Fe(CO)3), 1742 (s, CvO).
1H
NMR (500 MHz, CDCl3): δ = 5.79–5.77 (m, 1H, H2), 3.04 (Ψd,
J = 2.2 Hz, 1H, H4), 2.03 (Ψd, J = 14.0 Hz, 1H, H6), 1.64 (Ψd,
J = 14.0 Hz, 1H, H6), 1.26 (s, 9H, H11/H14), 1.19 (s, 9H,
H11/H14), 1.14 (Ψd, J = 2.9 Hz, 6H, H7, H8). 13C NMR
(125 MHz, CDCl3): δ = 210.2 (Fe(CO)3), 177.1 (C9/C12), 176.7
(C9/C12), 122.5 (C3), 93.5 (C1), 76.4 (C2), 69.1 (C4), 44.7 (C6),
39.2 (C10/C13), 39.0 (C10/C13), 35.7 (C5), 34.7(C7/C8), 30.7
(C7/C8), 27.0(C11/C14), 26.9 (C11/C14). LR-MS (DIP-MS,
70 eV): m/z (%) = 420 (1, [M − CO]+), 392 (3, [M − 2CO]+),
364 (34, [M − 3CO]+), 348 (2), 321 (8), 280 (25), 265 (12),
252 (15), 196 (17), 195 (24), 179 (14), 157 (5), 135 (6), 111 (7),
96 (5), 85 (7), 57 (100), 56 (18, [Fe]+). HR-MS (DIP-MS, 70 eV):
m/z 392.129 ± 0.0004 (calcd ([M − 2CO]+): m/z 392.1286).
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